Key result
No quantitative mortality outcomes reported for HF phenotypes after endovascular therapy.
Why the study?
Does heart failure phenotype (HFrEF vs HFpEF) affect long-term mortality in patients undergoing endovascular therapy for symptomatic peripheral artery disease?
Cohort
Yes
Does heart failure phenotype (HFrEF vs HFpEF) affect long-term mortality in patients undergoing endovascular therapy for symptomatic peripheral artery disease?
Answers are grounded in this paper and cite their sources.
This study investigates whether the specific phenotype of heart failure (HFrEF vs HFpEF) confers incremental prognostic risk for long-term mortality in patients treated with endovascular therapy for symptomatic peripheral artery disease.
Heart failure (HF) frequently co-exists with peripheral artery disease (PAD) and is associated with adverse cardiovascular outcomes. Previous studies have shown that PAD and HF are associated with an increased mortality rate.1,2 The prognostic impact of HF phenotype after endovascular therapy (EVT) remains insufficiently characterised. Whether heart failure reduced ejection fraction (HFrEF) confers incremental risk compared with heart failure with preserved ejection fraction (HFpEF) in this setting is unclear.
No takes yet. Share an insight, caveat, or question.
Shima et al. (2026) conducted a cohort in Symptomatic Peripheral Artery Disease and Heart Failure. Heart failure reduced ejection fraction (HFrEF) vs. Heart failure with preserved ejection fraction (HFpEF) was evaluated on Long term mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: